Literature DB >> 9454764

Characterization of functional vanilloid receptors expressed by mast cells.

T Bíró1, M Maurer, S Modarres, N E Lewin, C Brodie, G Acs, P Acs, R Paus, P M Blumberg.   

Abstract

Capsaicin and its ultrapotent analog resiniferatoxin (RTX) act through specific vanilloid receptors on sensory neurons. The C-type receptor is coupled to 45Ca uptake, whereas the R-type is detectable by [3H]RTX binding. We describe here specific vanilloid responses in murine mast cells (MCs). In the MC lines and in bone marrow-derived mast cells, capsaicin and RTX induced 45Ca uptake similarly to that observed for cultured rat dorsal root ganglion neurons (DRGs). This response was antagonized by the antagonists capsazepine and ruthenium red. As in DRGs, pretreatment of MCs with capsaicin or RTX induced desensitization to subsequent stimulation of 45Ca uptake. The potency for desensitization by RTX in the MCs corresponded to that for 45Ca uptake, whereas in DRGs it occurred at significantly lower concentrations corresponding to that for the high-affinity [3H]RTX binding site. Consistent with this difference, in MCs we were unable to detect [3H]RTX binding. Vanilloids were noncytotoxic to the MCs, in contrast to the DRGs. Although vanilloids did not cause degranulation in MCs, in the P815 clone capsaicin evoked selective interleukin-4 release. We conclude that certain MCs possess vanilloid receptors, but only the C-type that functions as a channel. Our finding that MCs can respond directly to capsaicin necessitates a reevaluation of the in vivo pathway of inflammation in response to vanilloids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454764

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  Without nerves, immunology remains incomplete -in vivo veritas.

Authors:  Andrew J Shepherd; James E G Downing; Jaleel A Miyan
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

2.  Distribution of the vanilloid (capsaicin) receptor type 1 in the human stomach.

Authors:  Maria-Simonetta Faussone-Pellegrini; Antonio Taddei; Elisa Bizzoco; Massimo Lazzeri; Maria Giuliana Vannucchi; Paolo Bechi
Journal:  Histochem Cell Biol       Date:  2005-07-22       Impact factor: 4.304

Review 3.  Dietary factors in rheumatic autoimmune diseases: a recipe for therapy?

Authors:  Shani Dahan; Yahel Segal; Yehuda Shoenfeld
Journal:  Nat Rev Rheumatol       Date:  2017-04-13       Impact factor: 20.543

Review 4.  TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.

Authors:  António Avelino; Francisco Cruz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-05-24       Impact factor: 3.000

5.  Lack of transient receptor potential vanilloid-1 enhances Th2-biased immune response of the airways in mice receiving intranasal, but not intraperitoneal, sensitization.

Authors:  Tetsuya Mori; Katsuyo Saito; Yasushi Ohki; Hirokazu Arakawa; Makoto Tominaga; Kenichi Tokuyama
Journal:  Int Arch Allergy Immunol       Date:  2011-06-29       Impact factor: 2.749

6.  Respiratory actions of vanilloid receptor agonists in the nucleus of the solitary tract: comparison of resiniferatoxin with non-pungent agents and anandamide.

Authors:  Dominic P Geraghty; Stuart B Mazzone
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

7.  Chemical nociception in the jejunum induced by capsaicin.

Authors:  B Schmidt; J Hammer; P Holzer; H F Hammer
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

8.  Significance of Conversation between Mast Cells and Nerves.

Authors:  Hanneke Pm van der Kleij; John Bienenstock
Journal:  Allergy Asthma Clin Immunol       Date:  2005-06-15       Impact factor: 3.406

9.  Capsaicin-induced joint inflammation is not blocked by local anesthesia.

Authors:  Michelle L Y Tang; Daniel A Haas; James W Hu
Journal:  Anesth Prog       Date:  2004

10.  TRPV1: a target for next generation analgesics.

Authors:  Louis S Premkumar; Parul Sikand
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.